Synta Pharmaceuticals (SNTA) gets hit hard in post-session trading after announcing mixed...


Synta Pharmaceuticals (SNTA) gets hit hard in post-session trading after announcing mixed interim results from its Phase 2b study of ganetespib, a treatment for advanced non-small cell lung cancer. The company says it plans to proceed to Phase 3. Shares -17% AH.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs